Industry Symposia

 

Wednesday, 19 April
11:30 a.m. – 12:30 p.m.
 		 ►  ABIOMED
Elevate Your Treatment Options: Aim for Heart Recovery
Room 401-404

►  CVRX
Baroreflex Activation Therapy: New Insights from the BeAT-HF Trial
Room 501-504

►  MEDTRONIC
Maintaining Proficiency in Long-Term HVAD Patient Management: Shared Experiences and Best Practices
Room 201/203

►  NATERA
Expanding Our Molecular Tools for Lung Allograft Assessment: Development of the TRIFECTA-Lung International Study
Room 205/207

►  TRANSMEDICS
Transplant Reimbursement and Economics Landscape for OCS Perfusion and NOP Services
Room 405-407
 

Thursday, 20 April
11:30 a.m. – 12:30 p.m. ►  ABBOTT
Playing the Long-Game: Changing Heart Failure to Heart Success
Room 603/605

►  CAREDX
Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance
Room 205/207

►  NATERA
Cementing the Value of Prospera Heart dd-cfDNA as a Non-Invasive Transplant Assessment
Room 405-407

►  PARAGONIX, INC.
Beyond Limits: Harnessing Advanced Preservation to Enhance Donor Lung Placement
Room 501-504

►  TRANSMEDICS
TransMedics Organ Care System (OCS™) State of the Art Heart and Lung Perfusion & Assessment Symposium – Transforming The Standard of Care
Room 401-404
 

Friday, 21 April
11:30 a.m. – 12:30 p.m. ►  CAREDX
Just Breathe - Facing Clinical Challenges in Lung Transplantation 
Room 205/207

►  MERCK
Addressing Risk of HF Rehospitalization With an Additional Guideline-Recommended Medication Date Needed
Room 401-404

►  ONE LAMBDA
Expanding the Post-Transplant Toolkit with the MMDx® Heart & Lung Tests
Room 201/203

►  PARAGONIX, INC.
Resetting the Standard: Impact of Advanced Heart Preservation on Program Growth
Room 501-504

►  XVIVO
Breaking Down Barriers to Scale Up EVLP Usage
Room 405-407
 
 

Wednesday, 19 April, 2023

ABIOMED
 Elevate Your Treatment Options: Aim for Heart Recovery
11:30 a.m. – 12:30 p.m.  |  Room 401-404
Core Therapy: HEART
Primary Practice Area: Cardiothoracic Surgery
Secondary Practice Area: Cardiology

This program is designed to explore the concept of heart recovery with Impella. Emerging science has shown myocardial recovery is possible.  Hear from your peers how they have incorporated heart recovery as the first option for advanced heart failure patients.

Moderator:
Roberta Bogaev-Chapman, MD, MSc,

Speakers:
Rob Dowling, MD, The Christ Hospital and Lindner Research and Education Center, Cincinnati, OH USA
Bart Meyns, MD, PhD, UZ Leuven, Leuven, Belgium
Kanika Mody, MD, Hackensack University Medical Center, Hackensack, NJ USA
Jane Wilcox, MD, MSc, Northwestern University Feinberg School of Medicine, Chicago, IL USA
 
CVRX
 Baroreflex Activation Therapy: New Insights from the BeAT-HF Trial...and Beyond
11:30 a.m. – 12:30 p.m.  |  Room 501-504
Core Therapy: HEART
Primary Practice Area: Cardiology
Secondary Practice Areas: Cardiothoracic Surgery, Nursing & Allied Health

Join a multi-disciplinary faculty to discuss the unmet needs with guideline-directed medical therapy, and review the latest in clinical data, mechanism of action, and patient selection for the use of Barostim in patients with HFrEF

Challenges and Opportunities with GDMT
Luanda Grazette, MD, University of Miami, Miami, FL USA

New Insights from the BeAT-HF Clinical Study
Brian Howard, MD, Wellstar, Marietta, GA USA

Real World Experience with Barostim - What I’ve Learned from >30 Cases
Robert T. Cole, MD, Piedmont, Atlanta, GA USA

Barostim in the Advanced Heart Failure Cardiologist’s Toolbox
Patrick J McCann, MD, Prisma Health, Columbia, SC USA

Panel Discussion
 
MEDTRONIC
 Maintaining Proficiency in Long-Term HVAD Patient Management: Shared Experiences and Best Practices
11:30 a.m. – 12:30 p.m.  |  Room 501-504
Core Therapy: MCS
Primary Practice Area: Cardiology
Secondary Practice Areas: Cardiothoracic Surgery

This physician-led lunch symposium will discuss challenging case studies and best practice recommendations specific to HVAD patients and their long-term care.

Moderators:
Salpy Pamboukian, MD, University of Washington, Seattle, WA USA
Mark Slaughter, MD, University of Louisville School of Medicine, Louisville, KY USA

Challenging HVAD Cases: Utilization of Waveforms and Logfile
Christopher Hayward, MD, St. Vincent's Hospital, Sydney, NSW, Australia
Liviu Klein, MD, University of California San Francisco, San Francisco, CA USA

HVAD Patient Attrition Over Time: Importance of Networking and Maintaining Proficiency Among Centers
Jennifer Hajj, RN, Medical University of South Carolina, Charleston, SC USA
Ka Lee Kerk, RN, National Centre, Singapore, Singapore
 
NATERA
 Expanding Our Molecular Tools for Lung Allograft Assessment: Development of the TRIFECTA-Lung International Study
11:30 a.m. – 12:30 p.m.  |  Room 205/207
Core Therapy: LUNG
Primary Practice Area: Pulmonology
Secondary Practice Area: Cardiothoracic Surgery, Nursing & Allied Health, Pathology, Research & Immunology

Prospera In Clinical Practice; Hear from Dr. Aryal from INOVA Health about his real world, clinical experience and case studies where dd-cfDNA testing has augmented current clinical practice. Learn about the study design and hear from the study PI of the multi-site, international, TRIFECTA-Lung study investigating clinical utility of dd-cfDNA in lung transplantation.

Moderator:
David Ross, MD, Natera Inc., Austin, TX USA

Case Studies
Shambhu Aryal, MD INOVA Health, Fairfax, VA USA

TRIFECTA-Lung Study Design
Philip Halloran, MD, PhD, University of Alberta, AB Canada
 
TRANSMEDICS
 Transplant Reimbursement and Economics Landscape for OCS Perfusion and NOP Services
11:30 a.m. – 12:30 p.m.  |  Room 405-407
Core Therapy: TBD
Primary Practice Area: TBD
Secondary Practice Area: TBD

Moderators:
Puneet Garcha, MD, Baylor St. Luke's Medical Center, Houston, TX USA
Paul Young, Transplant Institute at Massachusetts General Hospital, Boston, MA USA

Real World Overview of OCS Reimbursement and Economic Value to Engage with Payors – Having the Midas Touch
Kimberly Nicoll, TransMedics Inc., Boston, MA USA

Overview of CMS Transplant Reimbursement via Cost Report – Facts vs. Fiction
Robert Howey, MBA, Toyon Associates, Inc., Franklin, TN USA

Establishing OCS NOP Transplant Consortiums and National Transplant Administration Working Group
Waleed Hassanein, MD, TransMedics Inc., Boston, MA USA

National Transplant Administration Working Group Panel Discussion and Q&A
Paul Myoung, Massachusetts General Hospital, Boston, MA USA
Kimberly Nicoll, TransMedics Inc., Boston, MA USA
Robert Howey, Toyon Associates, Franklin, TN USA
Christopher Fowler, Mayo Clinic Arizona, Phoenix, AZ USA
Liz Reed, Transplant Institute at Henry Ford Hospital, Detroit, MI USA
 
 

Thursday, 20 April, 2023

ABBOTT
 Playing the Long-Game: Changing Heart Failure to Heart Success
11:30 a.m. – 12:30 p.m.  |  Room 603/605
Core Therapy: MCS
Primary Practice Area: Cardiology
Secondary Practice Areas: Anesthesiology & Critical Care, Cardiothoracic Surgery, Nursing & Allied Health

Treating Heart Failure is not a spectator sport.  Active patient management with advancements in medication and devices have improved heart failure patient outcomes.  An HCP team of panelists will share coaching insights and strategy on the purposeful steps they take in heart failure management to set patients up for long-term success.

Moderator:
Stavros Drakos, MD, PhD, FACC, University of Utah Health, Salt Lake City, UT USA

Heart Failure Treatment is Not a Spectator Sport: No More Waiting on the Sidelines
Catherine Marti, MD, MSc, Piedmont Heart Institute—Athens, Athens, GA USA

Elevating Your Game Plan: Optimizing with Heart Failure Therapies
Rebecca Cogswell, MD, University of Minnesota, Minneapolis, MN USA

You Miss 100% of the Shots You Never Take: Increasing Awareness and Access to Advanced Heart Failure Therapies
Christopher Salerno, MD, University of Chicago Medicine, Chicago, IL USA
 
CAREDX
 Challenging Cases in Post-Cardiac Transplant Care: The Role of Molecular Diagnostics in Surveillance
11:30 a.m. – 12:30 p.m.  |  Room 205/207
Core Therapy: HEART
Primary Practice Area: Cardiology
Secondary Practice Areas: Cardiothoracic Surgery

This symposium will focus on each panelist discussing the clinical validity and clinical utility of AlloSure Heart and AlloMap Heart for surveillance for heart transplant rejection as it relates to different clinical scenarios.

Moderators:
Jeremy Kobulnik, MD, CareDx, Chicago, IL USA
Eugene DePaquale, MD, University of Southern California, Los Angeles, CA USA

Speakers:
Albert J. Hicks III, MD, MPH, University of Maryland, Baltimore, MD USA
Kiran Khush, MD, Stanford University, Stanford, CA USA
Nir Uriel, MD, MSc, Columbia University, New York, NY USA
 
NATERA
 Cementing the Value of Prospera Heart dd-cfDNA as a Non-Invasive Transplant Assessment
11:30 a.m. – 12:30 p.m.  |  Room 405-407
Core Therapy: HEART
Primary Practice Area: Cardiology
Secondary Practice Area: Cardiothoracic Surgery, Nursing & Allied Health

Overview of three major clinical investigations designed to generate evidence in support of inclusion of dd-cfDNA analysis in standard clinical care of heart transplant patients. ProTECT (Prospera Test Evaluation in Cardiac Transplant) is an observational longitudinal, multi-center study observing patients undergoing heart transplant for whom Prospera testing is part of routine clinical care. DTRT (DNA-based transplant Rejection Test) is a multi-center observational study partially sponsored by the NIH to further validate the usage of Prospera in both adult and pediatric heart transplant patients. TRIFECTA-Heart is a multi-center, international, prospective study to calibrate dd-cfDNA levels from Prospera Heart transplant assessment against MMDx biopsy diagnosis of ACR and AMR.

Moderator:
Sangeeta Bhorade, MD, Natera Inc., Austin, TX USA

DTRT Study Design and Results
Shripasad Desplande, MD, Children’s National Hospital, Washington, DC USA

TRIFECTA-Heart Study Design and Early Results
Phil Halloran, MD, PhD, University of Alberta, Edmonton, AB Canada

First 100 Patient Eexperience from ProTECT Registry
Shelley Hall, MD, FACC, FHFSA, FAST, Baylor University Medical Center, Dallas, TX USA
 
PARAGONIX, INC.
 Beyond Limits: Harnessing Advanced Preservation to Enhance Donor Lung Procurement
11:30 a.m. – 12:30 p.m.  |  Room 501-504

Core Therapy: LUNG
Primary Practice Area: Cardiothoracic Surgery
Secondary Practice Area: Pulmonology

Results of the GUARDIAN-Lung Registry and Case Studies highlighting innovative uses of the LUNGguard Advanced Donor Lung Preservation Technology.

First Signs of Significance: Reduction in Post-transplant Complications in the GUARDIAN-LUNG Global Registry
Jasleen Kukreja, MD, MPH, UCSF Health, San Francisco, CA USA

Overcoming The Challenges of Overnight Lung Procurement Utilizing Timeshifting and LUNGguard
Howard J. Huang, MD, Houston Methodist Hospital, Houston, TX USA

Just Out of Reach: The Impact of Advanced Lung Preservation on Extended Ischemic Time and Long-Distance Donor Lung Procurement
Matthew G. Hartwig, MD, Duke University School of Medicine, Durham, NC USA
 
TRANSMEDICS
 TransMedics Organ Care System (OCS™) State of the Art Heart and Lung Extracorporeal Perfusion & Assessment Symposium – The New Frontiers
11:30 a.m. – 12:30 p.m.  |  Room 401-404

Core Therapy: TBD
Primary Practice Area: TBD
Secondary Practice Area: TBD

TBD

Moderators:
Kenneth McCurry, MD, Cleveland Clinic Foundation, Cleveland, OH USA
Carmelo Milano, MD, Duke University Medical Center, Durham NC USA

Impact of OCS Lung Perfusion Times on Post-Transplant Clinical Outcomes – Real-World Data from Thoracic Organ Perfusion (TOP) Registry
Gabriel Loor, MD, Baylor St. Luke’s Medical Center, Houston, TX USA

Long-Term Clinical Outcomes of The OCS Lung INSPIRE Randomized Trial
Gabriel Loor, MD, Baylor St. Luke’s Medical Center, Houston, TX, USA

First Annual Report from The OCS Heart Perfusion (OHP) Registry in the USA – Post-Approval Clinical Experience
Josef Stehlik, MD, University of Utah Health, Salt Lake City, UT USA

Standardized National Lung Procurement and OCS Perfusion Management (NOP) vs. Center Specific Process – Impact on Outcomes
Stephen Huddleston, MD, University of Minnesota, Minneapolis, MN USA

Update on Long-Term Clinical Outcomes from OCS DCD Heart Pivotal Trial
Amy Fiedler, MD, University of California San Francisco, San Francisco, CA USA

First Year Performance Review of The US National OCS Program (NOP) for Cardiothoracic Transplants
Waleed Hassanein, MD, TransMedics, Inc., Andover, MA USA

Panel Discussion and Q&A
 
 

Friday, 21 April, 2023

CAREDX
 Just Breathe - Facing Clinical Challenges in Lung Transplantation 
11:30 a.m. – 12:30 p.m.  |  Room 205/207
Core Therapy: LUNG
Primary Practice Area: Pulmonology
Secondary Practice Areas: Cardiothoracic Surgery

In this symposium, use of AlloSure Lung for surveillance of lung transplant patients will be discussed. In addition, use of AlloSure Lung in various clinical context will be discussed such as patients at heightened risk for complications following a biopsy, and following treatment of rejection.

Moderators:
Yuka Furuya, MD, CareDx, Minneapolis, MN USA
Debbie Levine, MD, Stanford University, Stanford, CA USA

Maximizing Clinical Utility of Cell-Free DNA in Lung Transplant Recipients: A Decision-Making Perspective
Nirmal Sharma, MD, Brigham and Women's Hospital, Boston, MA USA

Cell-Free DNA in Lung Transplantation: Advances and Clinical Applications
Anil Trindade, MD, Vanderbilt University, Nashville, TN USA

Tracking Allograft Health in Real-Time: Cell-Free DNA for Post-Treatment monitoring in Lung Transplantation
Hannah Manem, MD, University of Virginia, Charlottesville, VA USA

Q&A
 
MERCK
 Addressing Risk of HF Rehospitalization With an Additional Guideline-Recommended Medication Date Needed
11:30 a.m. – 12:30 p.m.  |  Room 401-404

Core Therapy: HEART
Primary Practice Area: Cardiology

This symposium will highlight the impact of HFrEF in the United States, discuss the increased risk of rehospitalization for HF with additional HFH, and review an outcome study in high-risk patients with HFrEF.

Speakers:
Matthew J. Budoff, MD
 
ONE LAMBDA
 Expanding the Post-Transplant Toolkit with the MMDx® Heart & Lung Tests
11:30 a.m. – 12:30 p.m.  |  Room 201/203

Core Therapy: HEART
Primary Practice Area: Cardiology
Secondary Practice Areas: Pathology, Pediatrics, Pulmonology

The emergence of gene expression profiling paired with machine learning algorithms has created new opportunities for improving risk stratification of allograft injury and rejection. This session will feature discussions on the utility of MMDx® Heart and Lung in adult and pediatric patients with a focus on utility data in both research and routine clinical settings.

Moderator:
Christopher Lawrence, BSc, LLM, MD(Res), FRCP, Thermo Fisher Scientific, Boston, MA USA

Use of MMDx® Heart in the Pediatric Population
Juan Alejos, MD, UCLA Mattel Children’s Hospital, Los Angeles, CA USA

Molecular Profiling of Tissue Biopsies in Lung Transplantation
Glen Westall, MD, PhD, Alfred Hospital, Melbourne, VIC Australia
 
PARAGONIX, INC.
 Resetting the Standard: Impact of Advanced Heart Preservation on Program Growth
11:30 a.m. – 12:30 p.m.  |  Room 501-504

Core Therapy: HEART
Primary Practice Area: Cardiothoracic Surgery
Secondary Practice Area: Cardiology

Results of the GUARDIAN Heart Registry and Case Studies highlighting innovative uses of the SherpaPak Cardiac Transport System Technology.

Real World Evidence and Latest Trends in Static Heart Preservation Collected from Over 1500 Patients in the Guardian-Heart Registry
David D'Alessandro, MD, Massachusetts General Hospital, Boston, MA USA

Impact of the SherpaPak Cardiac Transport System on Outcomes Across the Procurement Spectrum
Hannah Copeland, MD, FACS, FACC, Lutheran Health, Fort Wayne, IN USA

Moving the Needle: Driving Consistency with Advanced Heart Preservation to Achieve Program Goals
Nir Y. Uriel, MD, New York-Presbyterian / Columbia University Irving Medical Center, New York, NY USA
 
XVIVO
 Breaking Down Barriers to Scale Up EVLP Usage
11:30 a.m. – 12:30 p.m.  |  Room 405-407

Core Therapy: LUNG
Primary Practice Area: Cardiothoracic Surgery
Secondary Practice Area: Anesthesiology & Critical Care, Pulmonology

The scarcity of donated organs suitable for transplantation remains a challenge in lung transplantation. Ex Vivo Lung Perfusion (EVLP) has the potential to safely increase the utilization of donated lungs, but its adoption and integration into clinical practice has been limited by infrastructure and expertise. In this symposium you will learn about different collaborative approaches to break down some of the barriers and expand access to EVLP. Join the experts as they share their first-hand experience from different models to scaling up EVLP usage.

Moderators:
Edward Cantu, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA USA
Konrad Hoetzenecker, MD, Medical University of Vienna, Vienna, Austria

Collaborative Approaches to EVLP: The Perspective of a High Volume Lung Transplant Center
Kenneth McMurry, MD, Cleveland Clinic, Cleveland, OH USA

Transforming the Paradigm of Lung Transplantation to Increase Organ Utilization
Brandi Zofkie, MSBS-HDS, MPH, LungBioengineering Inc., Jacksonville, FL USA

Moving Towards Centralization of EVLP Within Scandinavia – Initial Steps Building "The Bridge"
Sandra Lindstedt, MD, PhD, Skåne University Hospital, Lund, Sweden